ES2450944T3 - Composición y comprimido que comprenden raltegravir - Google Patents

Composición y comprimido que comprenden raltegravir Download PDF

Info

Publication number
ES2450944T3
ES2450944T3 ES11168543.4T ES11168543T ES2450944T3 ES 2450944 T3 ES2450944 T3 ES 2450944T3 ES 11168543 T ES11168543 T ES 11168543T ES 2450944 T3 ES2450944 T3 ES 2450944T3
Authority
ES
Spain
Prior art keywords
raltegravir
methylglucamine
composition
tablet
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11168543.4T
Other languages
English (en)
Spanish (es)
Inventor
Daniela Stumm
Dominique Meergans
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Application granted granted Critical
Publication of ES2450944T3 publication Critical patent/ES2450944T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES11168543.4T 2011-06-01 2011-06-01 Composición y comprimido que comprenden raltegravir Active ES2450944T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11168543.4A EP2529741B1 (fr) 2011-06-01 2011-06-01 Composition et comprimé comprenant raltégravir

Publications (1)

Publication Number Publication Date
ES2450944T3 true ES2450944T3 (es) 2014-03-25

Family

ID=44188025

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11168543.4T Active ES2450944T3 (es) 2011-06-01 2011-06-01 Composición y comprimido que comprenden raltegravir

Country Status (7)

Country Link
US (1) US20140094478A1 (fr)
EP (2) EP2529741B1 (fr)
CA (1) CA2837241A1 (fr)
EA (1) EA201301355A1 (fr)
ES (1) ES2450944T3 (fr)
IL (1) IL229206A0 (fr)
WO (1) WO2012163893A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150166520A1 (en) * 2012-07-20 2015-06-18 Merck Sharp & Dohme Corp. Amido-substituted pyrimidinone derivatives useful for the treatment of hiv infection
WO2014064711A2 (fr) * 2012-10-22 2014-05-01 Hetero Research Foundation Procédés d'administration de raltégravir et de compositions de raltégravir
EP4093380A1 (fr) 2020-01-23 2022-11-30 Lupin Limited Compositions pharmaceutiques de raltégravir
EP4686471A1 (fr) 2024-08-01 2026-02-04 Fundacion Universitaria San Antonio (Ucam) Composé à utiliser comme inhibiteur de fascin1 dans le cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL161337A0 (en) 2001-10-26 2004-09-27 Angeletti P Ist Richerche Bio N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
EP1904067B2 (fr) * 2004-12-03 2017-10-11 Merck Sharp & Dohme Corp. Formulation pharmaceutique de derives de carboxamide , inhibiteurs de l'hiv integrase, comprenant une composition a liberation contrôlee
WO2007087188A2 (fr) * 2006-01-20 2007-08-02 Merck & Co., Inc. Comprimes et granules au gout masque
ES2389752T3 (es) * 2007-12-14 2012-10-31 Ardea Biosciences, Inc. Inhibidores de la transcriptasa inversa
EP2545048B1 (fr) * 2010-04-01 2014-10-08 Teva Pharmaceutical Industries Ltd. Sels de raltégravir et leurs formes cristallines
EP2694497A1 (fr) * 2011-04-06 2014-02-12 Lupin Limited Nouveaux sels de raltégravir

Also Published As

Publication number Publication date
EA201301355A1 (ru) 2014-05-30
EP2529741A1 (fr) 2012-12-05
CA2837241A1 (fr) 2012-12-06
IL229206A0 (en) 2014-01-30
EP2529741B1 (fr) 2014-02-12
WO2012163893A1 (fr) 2012-12-06
US20140094478A1 (en) 2014-04-03
EP2714044A1 (fr) 2014-04-09

Similar Documents

Publication Publication Date Title
KR102684756B1 (ko) 엔잘루타미드를 함유하는 경구 투여용 의약 조성물
JP2022153652A (ja) 崩壊が改善された経口用固形製剤組成物及びその製造方法
TW200821298A (en) Pharmaceutical compositions
KR20130091319A (ko) 4-아미노-5-플루오로-3-[6-(4-메틸피페라진-1-일)-1ｈ-벤즈이미다졸-2-일]-1ｈ-퀴놀린-2-온 락테이트 일수화물을 포함한 제약 조성물
ES2970132T3 (es) Composición farmacéutica que comprende besilato de lenvatinib
US20070071813A1 (en) Novel dosage formulation
WO2007119792A1 (fr) Comprimé à délitement rapide obtenu par compression directe à sec
JP5775085B2 (ja) ｃ−ＭＥＴキナーゼ阻害剤の製剤
JP6680297B2 (ja) 経口投与用医薬組成物
EA027641B1 (ru) Продукт сомикронизации, включающий ацетат улипристала
ES2450944T3 (es) Composición y comprimido que comprenden raltegravir
US10278969B2 (en) Pharmaceutical dosage forms
WO2006064906A1 (fr) Composition amorphe
ES2625012T3 (es) Producto de comicronización que comprende un modulador selectivo del receptor de progesterona
JP6063379B2 (ja) 固形医薬組成物
JP7641098B2 (ja) リバーロキサバン含有錠剤
JP7406349B2 (ja) イブプロフェン含有経口用医薬製剤
JPWO2015199115A1 (ja) 経口投与用医薬組成物
RU2830564C2 (ru) Фармацевтическая композиция для перорального введения, содержащая энзалутамид
JP2018123115A (ja) 経口固形製剤
JP2024539060A (ja) 医薬組成物
JP2012184171A (ja) 固形医薬組成物及び医薬製剤
JP2005194225A (ja) 胃内崩壊性錠剤
JP2016204346A (ja) アリピプラゾール医薬品製剤
CN103301116A (zh) 口服医药组合物